Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease and tenofovir-related toxicity

Keyphrases

• Bone Disease 100%
• Low Bone Mineral Density 100%
• Human Immunodeficiency Virus Infection 100%
• Hypogonadism 100%
• Tenofovir 100%
• Endocrine Complications 100%
• HIV Infection 66%
• Osteoporosis 66%
• Bone Demineralization 66%
• Clinical Significance 33%
• Renal Disease 33%
• Highly Active Antiretroviral Therapy (HAART) 33%
• Comorbidity 33%
• Increasing Age 33%
• Patient Care 33%
• Osteomalacia 33%
• HIV Patients 33%
• Improved Survival 33%
• Antiretroviral Therapy 33%
• Effective Management 33%
• Population Aging 33%
• Drug Toxicity 33%
• Fragility Fracture 33%
• Osteonecrosis 33%
• Antiretroviral Agents 33%
• Bone Pathology 33%
• Age-related Comorbidities 33%
• Metabolic Issue 33%
• Antiretroviral Toxicity 33%

Medicine and Dentistry

• Bone Disease 100%
• Bone Density 100%
• Human Immunodeficiency Virus Infection 100%
• Hypogonadism 100%
• Tenofovir 100%
• Human Immunodeficiency Virus 66%
• Osteoporosis 66%
• Bone Decalcification 66%
• Health Care Cost 33%
• Highly Active Antiretroviral Therapy 33%
• Bone Necrosis 33%
• Antiretroviral Therapy 33%
• Fragility Fracture 33%
• Osteomalacia 33%
• Drug Toxicity 33%
• Bone Pathology 33%
• Antiretrovirus Agent 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Bone Disease 100%
• Human Immunodeficiency Virus Infection 100%
• Hypogonadism 100%
• Tenofovir 100%
• HIV 66%
• Bone Demineralization 66%
• Syndrome 33%
• Osteomalacia 33%
• Fragility Fracture 33%
• Bone Necrosis 33%
• Drug Toxicity 33%
• Antiretrovirus Agent 33%